The estimated Net Worth of William Robert Elder is at least $367 mil dollars as of 16 November 2020. Mr Elder owns over 15,000 units of Diffusion Pharmaceuticals Inc stock worth over $66,000 and over the last 4 years he sold DFFN stock worth over $0. In addition, he makes $300,567 as Gen. Counsel & Corp. Sec. at Diffusion Pharmaceuticals Inc.
Mr has made over 1 trades of the Diffusion Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of DFFN stock worth $9,900 on 16 November 2020.
The largest trade he's ever made was buying 15,000 units of Diffusion Pharmaceuticals Inc stock on 16 November 2020 worth over $9,900. On average, Mr trades about 2,500 units every 0 days since 2020. As of 16 November 2020 he still owns at least 15,000 units of Diffusion Pharmaceuticals Inc stock.
You can see the complete history of Mr Elder stock trades at the bottom of the page.
William Robert Elder J.D. is the Gen. Counsel & Corp. Sec. at Diffusion Pharmaceuticals Inc.
As the Gen. Counsel & Corp. Sec. of Diffusion Pharmaceuticals Inc, the total compensation of Mr D at Diffusion Pharmaceuticals Inc is $300,567. There are 3 executives at Diffusion Pharmaceuticals Inc getting paid more, with Dr. Robert J. Cobuzzi Jr. having the highest compensation of $536,938.
Mr D is 38, he's been the Gen. Counsel & Corp. Sec. of Diffusion Pharmaceuticals Inc since . There are 4 older and no younger executives at Diffusion Pharmaceuticals Inc. The oldest executive at Diffusion Pharmaceuticals Inc is Dr. David Randolph Jones M.D., 58, who is the Sr. Medical Advisor.
William's mailing address filed with the SEC is 300 E. MAIN ST. SUITE 201, , CHARLOTTESVILLE, VA, 22902.
Over the last 9 years, insiders at Diffusion Pharmaceuticals Inc have traded over $0 worth of Diffusion Pharmaceuticals Inc stock and bought 61,786 units worth $39,139 . The most active insiders traders include Robert Joseph Jr. Cobuzzi, Isaac Blech, eJane H Hollingsworth. On average, Diffusion Pharmaceuticals Inc executives and independent directors trade stock every 60 days with the average trade being worth of $26,721. The most recent stock trade was executed by Diana M Lanchoney on 30 June 2023, trading 232 units of DFFN stock currently worth $1,021.
diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company is developing its lead drug, trans sodium crocetinate (tsc), which has received orphan drug designation from the fda for use in a number of cancers in which tumor hypoxia (oxygen deprivation) diminishes the efficacy of current treatments. tsc targets the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancerous cells more vulnerable to the therapeutic effects of conventional radiation and chemotherapy. the company is poised to begin a pivotal phase 3 trial in glioblastoma (gbm) in 2016. other programs include planned phase 2/3 trials in pancreatic cancer and brain metastases. because tsc’s novel mechanism safely re-oxygenates a wide range of tumor types, its use is not limited to a specific tumor tissue, but
Diffusion Pharmaceuticals Inc executives and other stock owners filed with the SEC include: